Ankur Vaid
#426Joint Managing Director & CEO
42
Age
23y
Exp
19y
Tenure
5/10
Risk
🎓 B.Tech Chemical Engineering · Rashtrasant Tukadoji Maharaj Nagpur University
📜 MBA · Rochester Institute of Technology
🏛️ None
CompensationTBP
Personality
5
Open
7
Cons
4
Extr
5
Agre
4
Neur
Concord Biotech
Healthcare · Mid Cap
High Growth · Founder-Centric
About
Ankur Vaid is the Joint Managing Director & CEO of Concord Biotech, a Mid Cap company in the Healthcare sector with a market cap of ₹12K Cr. A Pragmatic leader with 23 years of experience, he is known for data-driven decision-making and organic builder strategy. Focuses on steady, high-barrier manufacturing excellence within the fermentation-based biotechnology segment.
FAQ
What is Ankur Vaid's leadership style?
Ankur Vaid is classified as a Pragmatic leader. He is data-driven in decision-making, with a category creator motivation and steady-marathon pace of execution.
What is Ankur Vaid's educational background?
Ankur Vaid holds a B.Tech Chemical Engineering from Rashtrasant Tukadoji Maharaj Nagpur University and a MBA from Rochester Institute of Technology.
Who is the CEO of Concord Biotech?
Ankur Vaid is the Joint Managing Director & CEO of Concord Biotech. He has been with the company for 19 years and in the current role for 14 years.
Leadership DNA
ArchetypePragmatic
MotivationCategory Creator
CrisisSteady Hand
DecisionData-Driven
GrowthOrganic Builder
PeopleNumbers Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerLearning Ground
BrandTechnical-Expert
FocusOperational Excellence
OrientationDeep Specialist
Leadership Evidence
“Focuses on steady, high-barrier manufacturing excellence within the fermentation-based biotechnology segment.”
⚡ Crisis●●●●○
Concord Biotech maintained its focus on complex fermentation-based manufacturing and R&D consistency even during global supply chain disruptions.
🎯 Motivation●●●●○
The company focused on becoming a global leader in niche, high-barrier-to-entry fermentation products rather than general generics.
👥 People●●●●○
The firm is characterized by its rigorous operational efficiency and data-centric approach to manufacturing excellence in a highly regulated industry.
📈 Growth●●●●●
Growth has been primarily driven by significant capital expenditure in internal manufacturing capacity and R&D infrastructure rather than inorganic acquisitions.
💡 Innovation●●●●○
The company excels at developing complex fermentation-based products and APIs by leveraging strong R&D to scale high-quality alternatives to existing global products.
🏃 Pace●●●●○
The firm follows a methodical, long-cycle approach to building complex manufacturing capabilities and regulatory approvals in the high-barrier-to-entry biotech sector.
🌱 Purpose●●●○○
Concord operates in the critical healthcare space of fermentation-based APIs, balancing its pursuit of market share with the mission of improving global access to affordable life-saving medicines.
🏷️ Brand●●●●●
Its market reputation is built on deep scientific proficiency in fermentation and the ability to navigate complex global regulatory standards for pharmaceutical ingredients.
🤝 Customer●●●●●
Concord operates primarily as a global supplier of fermentation-based APIs to large pharmaceutical companies rather than selling directly to end consumers.
💼 Employer●●●○○
As a specialized biotech player, it attracts professionals seeking deep technical expertise in fermentation technology and regulatory compliance within the niche API manufacturing landscape.
📋 Mandate
Needs to scale specialized fermentation-based API manufacturing to capture global market share in high-barrier pharmaceutical segments.
🏢 Culture●●●○○
High promoter stake and active leadership involvement, fostering a vision-heavy decision-making environment.
Financials
Revenue FY25₹1K Cr
PAT FY25₹372 Cr
Rev CAGR 5Y18.5%
OPM39.3%
NPM31.5%
ROE20.5%
ROCE25%
P/E39.8
Fwd P/E28.8
P/B6.8
D/E0.1
Promoter74.7%
Institutional12.6%
Mkt Cap₹12K Cr
Compensation
To Be Published
Data being verified from audited reports
